Ad26.RSV.preF 1*10^11 vp

BIOLOGICAL2 trials

Sponsors

Janssen Vaccines & Prevention B.V.

Conditions

Healthy

Phase 1

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

CompletedNCT02926430

Janssen Vaccines & Prevention B.V.Healthy

Start: 2016-11-08End: 2019-01-29Updated: 2019-02-19

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

CompletedNCT03502707

Janssen Vaccines & Prevention B.V.Healthy

Start: 2018-07-06End: 2022-05-16Updated: 2025-05-25

Related Papers

Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study

The Journal of Infectious Diseases2023-07-1119 citations